Latest price of rituxitinib in 2024

Ritlecitinib (Ritlecitinib) is an oral specific Janus-related kinase inhibitor (mainly irreversible inhibition of JAK3), used to treat moderate to severe alopecia areata. Alopecia areata is an autoimmune disease characterized by hair loss, resulting in patches of scalp or even complete baldness, along with thinning or loss of eyebrows and eyelashes. Janus kinase is a key step in immune activation, signaling to different cytokine receptors and promoting the expression of genes involved in the production of pro-inflammatory cytokines. Ritexitinib was found to reduce or reverse hair loss in patients with alopecia areata in multiple randomized controlled trials.

Rituxitinib was approved in the United States in 2023, following ruxolitinib (JAK1/2 inhibitor) in 2011, tofacitinib (JAK1/3 inhibitor) in 2012 and baricitinib (JAK1/3 inhibitor) in 2018. 1/2 inhibitor), it is the fourth small molecule JAK inhibitor to be approved and the second JAK inhibitor to be approved for the treatment of alopecia areata after baricitinib in 2022. Litxitinib is available in 50 mg capsules under the trade name Litfulo. The recommended dose is 50 mg once daily. The current indication is for severe alopecia areata (defined as hair loss of 50% or more) in adults and adolescents 12 years and older.

The original drug ritixitinib has been approved for marketing in China, but has not yet been included in the medical insurance system. Its common specifications are50mg*30 tablets, and the price tag per box may be as high as more than 3,000 yuan. In overseas markets, the price of the European version of the original drug may exceed RMB 10,000 per box (the price may fluctuate due to exchange rate changes). At the same time, generic drugs of ritexitinib are also being sold overseas. The ingredients of the drugs are basically the same as those of the original drug. For example, the price of a box of generic drugs produced in Laos is about more than 1,000 yuan.